Brain plaque therapy Leqembi launches in India at ₹21,682

The Takeaway

• The medication ranks as India’s first CDSCO-approved disease-modifying therapy for Alzheimer’s.
• Doctors need to verify amyloid pathology using cerebrospinal fluid or serum biomarkers before authorising this regimen.
• Strict medical observation is necessary to monitor for a serious side effect called ARIA.
• The manufacturer provides dedicated support programmes to help eligible individuals navigate access safely.

Japanese pharmaceutical company Eisai introduced its new medication to the local market on August 3. The formula relies on lecanemab-irmb. It actively clears toxic proteins from the brain. The primary goal is to intervene early and slow clinical decline.

Healthcare providers administer the solution intravenously. The medication ships exclusively in single-dose vials. The ingredient list includes arginine hydrochloride and polysorbate 80. It also relies on histidine, histidine hydrochloride monohydrate, and water for injection. Total treatment cost depends entirely on the specific body weight of the person receiving care.

Conventional management methods merely mask cognitive symptoms for a short period. This new monoclonal antibody physically binds to aggregated amyloid-beta instead. It addresses the underlying biology to actively reduce further plaque deposition.

Leqembi pricing and dosing details

The local rollout creates a direct showdown in the neurological sector. It competes directly against Eli Lilly’s donanemab. That alternative drug debuted earlier in May 2026.

The national dementia burden continues to escalate rapidly. Approximately 8.8 million Indians over the age of 60 lived with the condition in 2023. Forecasts suggest that figure will nearly double by 2036.

The Unboxed Truth

You can’t buy time back after a dementia diagnosis. Unbox Daily HQ views Leqembi as a critical biological intervention rather than a generic daily pill. The ₹21,682 vial price scales sharply because the necessary volume relies entirely on your physical weight. It demands careful logistical planning and a specialist to handle the administration schedule. Paying for a recurring hospital-administered IV infusion compares roughly to the financial structure of targeted chemotherapy. It’s a process that requires absolute commitment to the ongoing treatment plan.

Best for: Combating the root biology of Alzheimer’s during the initial stages.

Who Is This For: Adults aged 60 to 80 experiencing mild cognitive decline or mild dementia.

Courtesy: Eisai